164 related articles for article (PubMed ID: 36826995)
81. Odronextamab, a human CD20×CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial.
Bannerji R; Arnason JE; Advani RH; Brown JR; Allan JN; Ansell SM; Barnes JA; O'Brien SM; Chávez JC; Duell J; Rosenwald A; Crombie JL; Ufkin M; Li J; Zhu M; Ambati SR; Chaudhry A; Lowy I; Topp MS
Lancet Haematol; 2022 May; 9(5):e327-e339. PubMed ID: 35366963
[TBL] [Abstract][Full Text] [Related]
82. Early detection of T-cell lymphoma with T follicular helper phenotype by RHOA mutation analysis.
Dobson R; Du PY; Rásó-Barnett L; Yao WQ; Chen Z; Casa C; Ei-Daly H; Farkas L; Soilleux E; Wright P; Grant JW; Rodriguez-Justo M; Follows GA; Rashed H; Fabre M; Baxter EJ; Vassiliou G; Wotherspoon A; Attygalle AD; Liu H; Du MQ
Haematologica; 2022 Feb; 107(2):489-499. PubMed ID: 33567811
[TBL] [Abstract][Full Text] [Related]
83. Follicular helper T-cell lymphomas: disease spectrum, relationship with clonal hematopoiesis, and mimics. A report of the 2022 EA4HP/SH lymphoma workshop.
Ondrejka SL; Amador C; Climent F; Ng SB; Soma L; Zamo A; Dirnhofer S; Quintanilla-Martinez L; Wotherspoon A; Leoncini L; de Leval L
Virchows Arch; 2023 Sep; 483(3):349-365. PubMed ID: 37500795
[TBL] [Abstract][Full Text] [Related]
84. Increased ratio of ICOS(+) /PD-1(+) follicular helper T cells positively correlates with the development of human idiopathic membranous nephropathy.
Shi X; Qu Z; Zhang L; Zhang N; Liu Y; Li M; Qiu J; Jiang Y
Clin Exp Pharmacol Physiol; 2016 Apr; 43(4):410-6. PubMed ID: 26845249
[TBL] [Abstract][Full Text] [Related]
85. Heterozygosity for Roquinsan leads to angioimmunoblastic T-cell lymphoma-like tumors in mice.
Ellyard JI; Chia T; Rodriguez-Pinilla SM; Martin JL; Hu X; Navarro-Gonzalez M; Garcia JF; Delfau-Larue MH; Montes-Moreno S; Gaulard P; Cook MC; Walters G; Piris MA; Vinuesa CG
Blood; 2012 Jul; 120(4):812-21. PubMed ID: 22700722
[TBL] [Abstract][Full Text] [Related]
86. Enhanced IL-6/phosphorylated STAT3 signaling is related to the imbalance of circulating T follicular helper/T follicular regulatory cells in patients with rheumatoid arthritis.
Niu Q; Huang ZC; Wu XJ; Jin YX; An YF; Li YM; Xu H; Yang B; Wang LL
Arthritis Res Ther; 2018 Aug; 20(1):200. PubMed ID: 30157931
[TBL] [Abstract][Full Text] [Related]
87. Rhesus macaque lymph node PD-1(hi)CD4+ T cells express high levels of CXCR5 and IL-21 and display a CCR7(lo)ICOS+Bcl6+ T-follicular helper (Tfh) cell phenotype.
Onabajo OO; George J; Lewis MG; Mattapallil JJ
PLoS One; 2013; 8(3):e59758. PubMed ID: 23527264
[TBL] [Abstract][Full Text] [Related]
88. Loss of Immune Tolerance Is Controlled by ICOS in Sle1 Mice.
Mittereder N; Kuta E; Bhat G; Dacosta K; Cheng LI; Herbst R; Carlesso G
J Immunol; 2016 Jul; 197(2):491-503. PubMed ID: 27296665
[TBL] [Abstract][Full Text] [Related]
89. Follicular helper T-cell lymphoma: a B-cell-rich variant of T-cell lymphoma.
Ruiz SJ; Cotta CV
Ann Diagn Pathol; 2015 Aug; 19(4):187-92. PubMed ID: 25913305
[TBL] [Abstract][Full Text] [Related]
90. Increased T follicular helper cells and germinal center B cells are required for cGVHD and bronchiolitis obliterans.
Flynn R; Du J; Veenstra RG; Reichenbach DK; Panoskaltsis-Mortari A; Taylor PA; Freeman GJ; Serody JS; Murphy WJ; Munn DH; Sarantopoulos S; Luznik L; Maillard I; Koreth J; Cutler C; Soiffer RJ; Antin JH; Ritz J; Dubovsky JA; Byrd JC; MacDonald KP; Hill GR; Blazar BR
Blood; 2014 Jun; 123(25):3988-98. PubMed ID: 24820310
[TBL] [Abstract][Full Text] [Related]
91. [Analysis of clinicopathological and molecular abnormalities of angioimmunoblastic T-cell lymphoma].
Shi YF; Wang HJ; Liu WP; Mi L; Long MP; Liu YF; Lai YM; Zhou LX; Diao XT; Li XH
Beijing Da Xue Xue Bao Yi Xue Ban; 2023 Jun; 55(3):521-529. PubMed ID: 37291929
[TBL] [Abstract][Full Text] [Related]
92. Aberrant expansion of follicular helper T cell subsets in patients with systemic lupus erythematosus.
Jin X; Chen J; Wu J; Lu Y; Li B; Fu W; Wang W; Cui D
Front Immunol; 2022; 13():928359. PubMed ID: 36119056
[TBL] [Abstract][Full Text] [Related]
93. Higher frequency of peripheral blood interleukin 21 positive follicular helper T cells in patients with ankylosing spondylitis.
Xiao F; Zhang HY; Liu YJ; Zhao D; Shan YX; Jiang YF
J Rheumatol; 2013 Dec; 40(12):2029-37. PubMed ID: 24187103
[TBL] [Abstract][Full Text] [Related]
94. Higher frequencies of circulating ICOS
Zhang Z; Shi Y; Yang K; Crew R; Wang H; Jiang Y
Autoimmunity; 2017 Dec; 50(8):458-467. PubMed ID: 29025273
[TBL] [Abstract][Full Text] [Related]
95. Circulating CCR7+ICOS+ Memory T Follicular Helper Cells in Patients with Multiple Sclerosis.
Fan X; Jin T; Zhao S; Liu C; Han J; Jiang X; Jiang Y
PLoS One; 2015; 10(7):e0134523. PubMed ID: 26231034
[TBL] [Abstract][Full Text] [Related]
96. Impact of HIV-1 Infection and Antigen Class on T Follicular Helper Cell Responses to Pneumococcal Polysaccharide-Protein Conjugate Vaccine-13.
Jha V; Nicholson LK; Gardner EM; Rahkola JT; Pratap H; Scott J; Borgeson M; Jacobelli J; Janoff EN
J Immunol; 2021 May; 206(10):2402-2411. PubMed ID: 33931485
[TBL] [Abstract][Full Text] [Related]
97. CD8 Treg-Mediated Suppression of Naive CD4+ T Cell Differentiation into Follicular Helper T Cells.
Kasahara TM; Gupta S
Int Arch Allergy Immunol; 2022; 183(6):682-692. PubMed ID: 34959235
[TBL] [Abstract][Full Text] [Related]
98. Non-coding autoimmune risk variant defines role for ICOS in T peripheral helper cell development.
Kim T; Martínez-Bonet M; Wang Q; Hackert N; Sparks JA; Baglaenko Y; Koh B; Darbousset R; Laza-Briviesca R; Chen X; Aguiar VRC; Chiu DJ; Westra HJ; Gutierrez-Arcelus M; Weirauch MT; Raychaudhuri S; Rao DA; Nigrovic PA
Nat Commun; 2024 Mar; 15(1):2150. PubMed ID: 38459032
[TBL] [Abstract][Full Text] [Related]
99. Enhancer of Zeste Homolog 2 Inhibitor SHR2554 in Relapsed or Refractory Peripheral T-cell Lymphoma: Data from the First-in-Human Phase I Study.
Song Y; Jin Z; Li ZM; Liu Y; Li L; He C; Su H; Zhou H; Li K; Hao S; Zuo X; Wu J; Li D; Wu M; Sun X; Qi J; Cai Z; Li Z; Li Y; Huang Y; Shen J; Xiao Z; Zhu J
Clin Cancer Res; 2024 Apr; 30(7):1248-1255. PubMed ID: 38190117
[TBL] [Abstract][Full Text] [Related]
100. INDUCE-2: A Phase I/II, open-label, two-part study of feladilimab in combination with tremelimumab in patients with advanced solid tumors.
Hilton JF; Ott PA; Hansen AR; Li Z; Mathew M; Messina CH; Dave V; Ji X; Karpinich NO; Hirschfeld S; Ballas M; Zandberg DP
Cancer Immunol Immunother; 2024 Feb; 73(3):44. PubMed ID: 38349570
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
